TG Therapeutics Initiates Phase 2 Trial for Briumvi in Treatment-Resistant Schizophrenia
TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2 clinical trial to evaluate the efficacy and safety of its drug candidate, Briumvi, in adults with treatment-resistant schizophrenia. The open-label study will enroll approximately 60 patients who have not responded adequately to standard antipsychotic treatments.
Topics: biotech Briumvi pharmaceuticals schizophrenia